Announcements Trials

Browse Landscape

Status

Recruiting 3 Completed 3 Active not recruiting 3 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Sarcoma 5 Pancreatic Neoplasms 5 Multiple Myeloma 5 Melanoma 5 Prostatic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Ovarian Neoplasms 3 Lymphoma, Large B-Cell, Diffuse 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3 Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Recurrence 2 Primary Myelofibrosis 2 Non-Muscle Invasive Bladder Neoplasms 2 Neuroblastoma 2 Neoplasm Metastasis 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Lymphoma 2 Head and Neck Neoplasms 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Available × INDUSTRY × Desmoid Tumors × Clear all

NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡